Milestones 2018-01-03T15:26:21+00:00

Project Description


  • Mechanistic target of GLY-230 shown to induce changes in retinal cells associated with diabetic retinopathy

  • GLY-230 corrects abnormalities of diabetic retinopathy in experimental diabetes

  • GLY-230 shows efficacy in Phase 2 clinical trial

  • GLY-230 shows positive results in experimental model of Alzheimer’s disease

  • GLY-220 prevents changes of macrovascular disease in preclinical studies

  • Humanized A717 mAb and single-chain A717 successfully developed.